Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the company’s positive Phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer. The data were presented at the 2025 Annual Meeting of the American Society for Radiation Oncology or ASTRO. Radiation therapy remains the standard of care for this patient population but has seen little advancement in more than two decades. Despite current treatments, approximately 30% of patients experience disease recurrence within 10 years, underscoring a significant unmet need. The pivotal Phase 3 study was a randomized, double-blind, placebo-controlled, multicenter trial enrolling 745 patients. Participants were randomized 2:1 to receive either CAN-2409 plus valacyclovir in combination with standard-of-care radiation therapy or standard-of-care radiation alone. The investigational therapy was administered both before and during radiation treatment. The trial met its primary endpoint, demonstrating 30% improvement in disease-free survival, 38% improvement in prostate cancer-specific disease-free survival and at two years, a pathological complete response rate of 80.4% in the CAN-2409 arm, compared with 63.6% in the control arm. Importantly, Candel presented additional subgroup analyses showing that the efficacy of CAN-2409 was consistent regardless of the radiation modality used in the trial. This independence underscores the broad applicability of the therapy across different treatment settings. Dr. Tak emphasized the significance of the findings, noting that CAN-2409 represents the first potential advancement in localized, non-metastatic prostate cancer in more than 20 years. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch